Lilly to Acquire Calytrix Bio for Up to $1.5B in Mutant CALR Antibody Deal

Lilly to Acquire Calytrix Bio for Up to $1.5B in Mutant CALR Antibody Deal
Lilly to Acquire Calytrix Bio for Up to $1.5B in Mutant CALR Antibody Deal

Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody

November, 18 2026
Click to view quick news summary (Spoiler)

Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody targeting mutant calreticulin in two rare blood disorders.

Eli Lilly and Co. agreed to acquire Calytrix Bio for up to $1.5 billion in cash. The total includes an upfront payment and further payments tied to clinical and regulatory milestones. Lilly shares rose 0.94% as of 11:00 a.m. ET.

Calytrix's lead program is a preclinical antibody that targets mutant calreticulin, a genetic alteration behind essential thrombocythemia and myelofibrosis. Both are rare disorders that cause the bone marrow to produce too many abnormal blood cells. The antibody is designed to hit both main types of the mutation, depleting the cells that drive the disease while sparing healthy blood production.

Current treatments manage symptoms rather than target those cells. Calytrix CEO Brad Prosek said patients deserve therapies that do more than manage symptoms.

The deal adds to Lilly's blood cancer business, which already includes the approved drug Jaypirca, and follows its $2.3 billion purchase of Ajax Therapeutics earlier this year.

The latest transaction includes an upfront payment and additional payments tied to clinical trial and regulatory milestones, Calytrix said. It did not disclose the size of the upfront payment or when the deal is expected to close.

Calytrix's lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis – rare blood disorders that cause the bone marrow to produce excessive abnormal blood cells. The drug has not yet entered human clinical trials.

The treatment targets mutated calreticulin, a genetic alteration that drives disease in patients with the blood disorders. Calytrix said it is designed to attack abnormal cells driving the illness while leaving healthy blood-forming cells intact.

Current treatments manage symptoms and reduce complications rather than directly target the underlying disease-causing cells, according to the company.

Calytrix, based in Wellesley Hills, Massachusetts, was founded by J.P. Morgan Life Sciences Private Capital, the venture capital arm within J.P. Morgan Asset Management. Its investors include Westlake BioPartners and Avoro Ventures.

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.

Accept